ESCITALOPRAM TABLET

Quốc gia: Canada

Ngôn ngữ: Tiếng Anh

Nguồn: Health Canada

Thành phần hoạt chất:

ESCITALOPRAM (ESCITALOPRAM OXALATE)

Sẵn có từ:

RANBAXY PHARMACEUTICALS CANADA INC.

Mã ATC:

N06AB10

INN (Tên quốc tế):

ESCITALOPRAM

Liều dùng:

20MG

Dạng dược phẩm:

TABLET

Thành phần:

ESCITALOPRAM (ESCITALOPRAM OXALATE) 20MG

Tuyến hành chính:

ORAL

Các đơn vị trong gói:

100

Loại thuốc theo toa:

Prescription

Khu trị liệu:

SELECTIVE-SEROTONIN REUPTAKE INHIBITORS

Tóm tắt sản phẩm:

Active ingredient group (AIG) number: 0150435004; AHFS:

Tình trạng ủy quyền:

APPROVED

Ngày ủy quyền:

2015-05-05

Đặc tính sản phẩm

_ _
_Pr_
_ESCITALOPRAM (Escitalopram Tablets, Mfr. Std.) Product Monograph _
_Page 1 of 59_
PRODUCT MONOGRAPH
PR
ESCITALOPRAM
Escitalopram Tablets, Mfr. Std.
10 mg and 20 mg escitalopram (as escitalopram oxalate)
ANTIDEPRESSANT / ANTIOBSESSIONAL
Ranbaxy Pharmaceuticals Canada Inc.
DATE OF PREPARATION:
2680 Matheson Blvd. E., Suite 200
March 24, 2015
Mississauga, Ontario
L4W 0A5
SUBMISSION CONTROL NO: 181798
Trademark owned by Ranbaxy Laboratories Limited
_ _
_Pr_
_ESCITALOPRAM (Escitalopram Tablets, Mfr. Std.) Product Monograph _
_Page 2 of 59_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................12
DRUG INTERACTIONS
..................................................................................................26
DOSAGE AND ADMINISTRATION
..............................................................................32
OVERDOSAGE
................................................................................................................35
ACTION AND CLINICAL PHARMACOLOGY
............................................................36
STORAGE AND STABILITY
..........................................................................................38
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................38
PART II: SCIENTIFIC INFORMATION
...............................................................................39
PHARMACEUTICAL INFORMATION
..............................